vyzulta coupon

VyzultA savings coupon
MOST ELIGIBLE COMMERCIALLY INSURED PATIENTS PAY NO MORE THAN $30 ON THEIR FIRST 2-MONTH PRESCRIPTION.*
Most eligible commercially insured covered patients pay no more than a $30 co-pay for the first 2-month prescription and $70 for eligible 2-month refills.

Most eligible commercially insured non-covered patients pay no more than $60 co-pay for the first 2-month prescription and $90 for eligible 2-month refills. Discounted prices are available for eligible uninsured patients. Terms and conditions apply, please see eligibility criteria and terms and conditions.

Discounted prices are available for eligible uninsured patients. Terms and conditions apply, please see eligibility criteria and terms and conditions.
save now
*This offer is only valid for eligible patients with commercial insurance. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. This offer is good only in the US at retail pharmacies owned and operated by Walgreen Co. (or its affiliates) or other participating independent retail pharmacies. This offer is not valid in Massachusetts or Minnesota or where otherwise prohibited, taxed, or otherwise restricted.
Click here for all eligibility criteria and terms and conditions that apply.

Sign up now for new offerings and information about VYZULTA.

Loading...

INDICATION

VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
  • Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
  • Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
  • Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
  • Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
  • If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
  • The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information >

SEE MORE

INDICATION

VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.